Nestin(+) tissue-resident multipotent stem cells contribute to tumor progression by differentiating into pericytes and smooth muscle cells resulting in blood vessel remodeling

Frontiers in Oncology

Volumn 4 JUN, Issue , 2014, Pages

  Klein, Diana ^a   Meissner, Nicole ^a   Kleff, Veronika ^b   Jastrow, Holger ^b   Yamaguchi, Masahiro ^c   Suleyman Ergun ^d   Jendrossek, Verena ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

mesenchymal stem cell; Nestin; Pericytes; Vascular remodeling; Vessel maturation

Indexed keywords

NESTIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL REMODELING; CANCER CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MEDICAL PROCEDURES; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PERICYTE; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; SMOOTH MUSCLE FIBER; TUMOR GROWTH; TUMOR XENOGRAFT; VASCULAR TUMOR; WESTERN BLOTTING;

EID: 84904633643     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00169     Document Type: Article

References (39)

1. Gaengel K, Genove G, Armulik A, Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol (2009) 29:630-8. doi: 10.1161/ATVBAHA.107.161521
2. Tilki D, Kilic N, Sevinc S, Zywietz F, Stief CG, Ergun S. Zone-specific remodeling of tumor blood vessels affects tumor growth. Cancer (2007) 110:2347-62. doi:10.1002/cncr.23024
3. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol (2003) 162:183-93. doi:10.1016/S0002-9440(10)63809-6
4. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol (2005) 7:452-64. doi:10.1215/S1152851705000232
5. Klein D, Weisshardt P, Kleff V, Jastrow H, Jakob HG, Ergun S. Vascular wall-resident CD44+ multipotent stem cells give rise to pericytes and smooth muscle cells and contribute to new vessel maturation. PLoS One (2011) 6:e20540. doi:10.1371/journal.pone.0020540
6. Tigges U, Komatsu M, Stallcup WB. Adventitial pericyte progenitor/mesenchymal stem cells participate in the restenotic response to arterial injury. J Vasc Res (2013) 50:134-44. doi:10.1159/000345524
7. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res (2005) 65:671-80.
8. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem (2006) 13:1845-57. doi:10.2174/092986706777585059
9. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 307:58-62. doi:10.1126/science.1104819
10. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 91:1071-121. doi:10.1152/physrev.00038.2010
11. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest (1999) 103:159-65. doi:10.1172/JCI5028
12. Ergun S, Tilki D, Oliveira-Ferrer L, Schuch G, Kilic N. Significance of vascular stabilization for tumor growth and metastasis. Cancer Lett (2006) 238:180-7. doi:10.1016/j.canlet.2005.06.033
13. Kano MR, Komuta Y, Iwata C, Oka M, Shirai YT, Morishita Y, et al. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci (2009) 100:173-80. doi:10.1111/j.1349-7006.2008.01003.x
14. Weisshardt P, Trarbach T, Durig J, Paul A, Reis H, Tilki D, et al. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem Cell Biol (2012) 137:391-401. doi:10.1007/s00418-011-0898-8
15. Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, et al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood (2013) 121:5192-202. doi:10.1182/blood-2013-03-490763
16. Ergun S, Tilki D, Klein D. Vascular wall as a reservoir for different types of stem and progenitor cells. Antioxid Redox Signal (2011) 15:981-95. doi:10.1089/ars.2010.3507
17. Klein D, Hohn HP, Kleff V, Tilki D, Ergun S. Vascular wall-resident stem cells. Histol Histopathol (2010) 25:681-9.
18. Kleff V, Sorg UR, Bury C, Suzuki T, Rattmann I, Jerabek-Willemsen M, et al. Gene therapy of beta(c)-deficient pulmonary alveolar proteinosis (beta(c)-PAP): studies in a murine in vivo model. Mol Ther (2008) 16:757-64. doi:10.1038/mt.2008.7
19. Yamaguchi M. Analysis of neurogenesis using transgenic mice expressing GFP with nestin gene regulatory regions. Chem Senses (2005) 30(Suppl 1):i117-8. doi:10.1093/chemse/bjh142
20. Klein D, Demory A, Peyre F, Kroll J, Augustin HG, Helfrich W, et al. Wnt2 acts as a cell type-specific, autocrine growth factor in rat hepatic sinusoidal endothelial cells cross-stimulating the VEGF pathway. Hepatology (2008) 47:1018-31. doi:10.1002/hep.22084
21. Matsuda Y, Hagio M, Ishiwata T. Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. World J Gastroenterol (2013) 19:42-8. doi:10.3748/wjg.v19.i1.42
22. Oikawa H, Hayashi K, Maesawa C, Masuda T, Sobue K. Expression profiles of nestin in vascular smooth muscle cells in vivo and in vitro. Exp Cell Res (2010) 316:940-50. doi:10.1016/j.yexcr.2009.10.025
23. Au P, Tam J, Fukumura D, Jain RK. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood (2008) 111:4551-8. doi:10.1182/blood-2007-10-118273
24. Klein D, Benchellal M, Kleff V, Jakob HG, Ergun S. Hox genes are involved in vascular wall-resident multipotent stem cell differentiation into smooth muscle cells. Sci Rep (2013) 3:2178. doi:10.1038/srep02178
25. Davidoff MS, Middendorff R, Enikolopov G, Riethmacher D, Holstein AF, Muller D. Progenitor cells of the testosterone-producing Leydig cells revealed. J Cell Biol (2004) 167:935-44. doi:10.1083/jcb.200409107
26. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J (2004) 18:338-40. doi:10.1096/fj.03-0271fje
27. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 456:809-13. doi:10.1038/nature07424
28. Lin MI, Sessa WC. Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell (2004) 6:529-31. doi:10.1016/S1535-6108(04)00340-X
29. Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol (2011) 55:261-8. doi:10.1387/ijdb.103167dr
30. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol (2005) 7:870-9. doi:10.1038/ncb1288
31. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J (1999) 18:3964-72. doi:10.1093/emboj/18.14.3964
32. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science (2006) 313:1785-7. doi:10.1126/science.1127592
33. Wickersheim A, Kerber M, de Miguel LS, Plate KH, Machein MR. Endothelial progenitor cells do not contribute to tumor endothelium in primary and metastatic tumors. Int J Cancer (2009) 125:1771-7. doi:10.1002/ijc.24605
34. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med (2005) 11:261-2. doi:10.1038/nm1200
35. Purhonen S, Palm J, Rossi D, Kaskenpaa N, Rajantie I, Yla-Herttuala S, et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A (2008) 105:6620-5. doi:10.1073/pnas.0710516105
36. Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L. Immunological characterization of multipotent mesenchymal stromal cells - The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy (2013) 15:1054-61. doi:10.1016/j.jcyt.2013.02.010
37. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature (2010) 466:829-34. doi:10.1038/nature09262
38. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell (2008) 3:301-13. doi:10.1016/j.stem.2008.07.003
39. Majesky MW. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol (2007) 27:1248-58. doi:10.1161/ATVBAHA.107.141069